Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Recruiting
N/A
Interventional Study
Carcinoma, Hepatocellular
Cirrhosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 4,700 (estimated)
- Sponsor
- VA Office of Research and Development · Federal
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in patients at high risk of developing HCC. The investigators hypothesize that HCC will be detected at e…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Cirrhosis due to any underlying etiology diagnosed by one or more of the following:
* Histology of liver biopsy
* Radiologic criteria (nodular liver, evidence of portal hypertension)
* Clinical signs of cirrhosis (gastroesophageal varices, ascites, hepatic encephalo…
Contacts